Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "compliance"

374 News Found

US FDA issues 17 observations for Biocon Biologics sites
News | September 01, 2022

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools


Wockhardt signs USFDA approved manufacturing partners
Drug Approval | August 22, 2022

Wockhardt signs USFDA approved manufacturing partners

The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner


QPharma launches Ti OrderPoint 2
Digitisation | August 19, 2022

QPharma launches Ti OrderPoint 2

OrderPoint was designed as an advanced DTR solution from its first release in 2016.


Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
News | August 04, 2022

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market


PIB: Quality control of Ayush drugs
Policy | August 03, 2022

PIB: Quality control of Ayush drugs


Casper Pharma completed USFDA pre-approval inspection
Drug Approval | July 31, 2022

Casper Pharma completed USFDA pre-approval inspection

The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.


Tealium launches customer data platform for pharma
Digitisation | July 27, 2022

Tealium launches customer data platform for pharma

Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors


Healthcare Triangle launches in Singapore; Leveraging AI and cloud in Asia Pacific Markets
Digitisation | July 26, 2022

Healthcare Triangle launches in Singapore; Leveraging AI and cloud in Asia Pacific Markets

The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.


USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list
Drug Approval | July 14, 2022

USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list

Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.